|
|
Post by omstem on Dec 6, 2015 7:33:49 GMT
I view this site regularly and post rarely. There are people who make sense and they are right.
Regarding Wotton not being an American, does not make sense. He is not a Japanese either and the company is being sold to a Japanese company. I am not against Japanese and I truly respect their vision and the ability to convert research into a commercial product. Look at the past few decades and you will realize the success of the companies that became household names. Sony, Cannon, Toshiba you name it. Be it tape recorders or VCRs or DVD players or cameras or TVs and even cars, the best brands are Japanese brands.
Dr. Lanza is a true American and he stuck to this company even when water coolers were being taken away or about to be taken away (not that he needs the water cooler to drench his thirst). He could have found a cushion job with another big company when Ocata or ACTC was finding it hard to survive.
What made this company being sold?
1. Is the science less superior?
2. Is this purely an issue of impediments in commercializing the product
If the second one is the issue, let us not blame the management and put the blame where it squarely belongs.
Every company involved in stem cell research is looking for a Japanese partner. Why?
Why even American companies are looking for a Japanese partner? What is the Japanese government doing that the US government failed to do? After all with companies involved in research and trials, the success depends upon the push they get from their respective governments.
|
|
|
|
Post by JHam on Dec 6, 2015 8:28:52 GMT
Watch the volume over the next week or so. If it continues dropping off and the share price stays at or just under $8.50 then it is very likely many shareholders are tendering. Once tendered, those shares can't be traded, which is why the volume would drop off as we get closer to 12/17. The clock is ticking, and in all honesty I think it is becoming increasingly unlikely anyone is coming to save us now. Those greedy self-serving b@stards (Wotton, BOD, business C-levels) will EACH be making many millions out of this deal, and it is directly at the expense of long retail shareholders. I am so angry at the way this deal went down, and how the possible 'small JV' turned into a buyout, coincidentally right about the same time the share price was 'mysteriously' shorted to half the level it had held for years, and for no apparent reason. To quote Wotton, "There are no fundamental changes to the company that would explain this sudden drop in share price"... Oh really mate? OH F'ING REALLY MATE?  So Astellus viewing insider info and suddenly changing from a small JV to wanting to buy the company, and the share price inexplicably being shorted to half its value all happening at around the same time was just a coincidence was it, you fat self-serving greedy b@stard? I believe Wotton knew exactly what was going on - how could he NOT know? - and he did nothing to fulfill his fiduciary duty to shareholders. NOTHING. In fact, I believe his actions above demonstrate deliberate culpability in what can only be considered outright fraud. And he's going to get away with it. Wotton's not an American, so he couldn't give a flying fk about the IP going offshore - as long as he gets to stuff his pockets full of shareholders money, then it's "no worries mate", and a big fat finger straight in the face of all the long retail shareholders. **************************************************..Sorry, but every time I think about this I get so pissed at how we've been blatantly screwed here. *EDIT - Nation bashing
I understand you are pissed and I don't care if you rant a little bit. But please refrain from bashing Wotton's nationality. That is definitely against the rules and is a good way to get banned in a hurry. We have members on this board from dozens of different countries and they should never feel intimidated to post because of it.JHam Be sure to check this edit. Thanks. |
|
|
|
Post by JHam on Dec 6, 2015 8:44:29 GMT
You've been reading icell again haven't you. This is a done deal..I also took the money. Believe me if there was ever an iota that they could hold out and do this alone they would have. I started calling some folks out on their outlandish predictions (no need to name them) and was called a troll. They made it hard for me to log on but that's cool, I canceled my membership before hand. In my opinion it's more harmful pumping than it is bashing. Folks over there put their lives,homes, and family on hold because of a few zealots over there and I called them out on it. Thanks jham in advance for letting me go off topic and say my piece. I'm finished....go geron!!!  By definition, it's not a done deal until the votes are counted.
Will 51% of shareholders tender their shares for $8.50? Hard to say IMO. I believe any institutions who recently bought and have an average cost of $6 or lower will vote "Yes", but I don't think that comprises more than 20% of the shares. Retailers will have the final say, and IMO a good number of them have an average cost close to $8.50 or higher and will be voting "No". I think the vote will be fairly close, and I don't think anyone can make any definitive statements one way or the other.
Per my prior posts, IMO there's both potential upside and downside from here. Upside if Astellas increases their offer or another offer surfaces, and downside if $8.50 is voted down and Astellas doesn't immediately announce a higher offer or walks.
Wishing the best for all holding.
I don't think it is just institutions. These 2 paragraphs from the 14D indicate to me that Jefferies is likely doing all they can to make this tender offer succeed. They have $3.8M on the line and since they can buy, sell, hold, or short, they are probably acquiring as many shares as they can on the open market and tendering them: Miscellaneous
Jefferies maintains a market in the securities of Ocata and, in the ordinary course of business, Jefferies and its affiliates may trade or hold securities of Ocata, Astellas and/or their respective affiliates for Jefferies’ own account and for the accounts of Jefferies’ customers and, accordingly, may at any time hold long or short positions in those securities. Jefferies and its affiliates in the past have provided and in the future may provide financial advisory and financing services unrelated to the Offer and the Merger to Ocata and its affiliates, for which services Jefferies and its affiliates have received and would expect to receive compensation, including, during the two-year period prior to the date of Jefferies’ opinion, having acted as lead joint bookrunning manager for a registered direct equity offering of Ocata in June 2015, for which services during such two-year period Jefferies and its affiliates received an aggregate fee of approximately $817,000. Although Jefferies and its affiliates had not provided financial advisory or financing services during the two-year period prior to the date of Jefferies’ opinion to Astellas for which Jefferies or its affiliates received compensation, Jefferies and its affiliates may provide such services to Astellas and its affiliates in the future, for which services Jefferies and its affiliates would expect to receive compensation.--- Item 5.
Persons/Assets Retained, Employed, Compensated or Used.
Under the terms of Jefferies’ engagement, Ocata has agreed to pay Jefferies for its financial advisory services in connection with the Offer and the Merger an aggregate fee currently estimated to be approximately $4.8 million, of which a portion was payable upon delivery of Jefferies’ opinion and approximately $3.8 million is payable contingent upon completion of the Offer. In addition, Ocata has agreed to reimburse Jefferies for its expenses, including fees and expenses of counsel, and to indemnify Jefferies and related parties against liabilities, including liabilities under federal securities laws, arising out of or in connection with the services rendered and to be rendered by Jefferies under its engagement. |
|
|
|
Post by JHam on Dec 17, 2015 17:28:41 GMT
Just saw this posted elsewhere:
OCATA-Update_from_Gary_Aronson_17-Dec-2015
Gary Aronson asked me to post this for him.
We are continuing to contact potential investors into Ocata. I had one glimmer of hope today, hopefully not too late. I spoke again with my friend, Mike West, PhD, CEO of BioTime (BTX). He said that I could relate that he has already gone on the public record as believing that the stem cell therapeutics industry is in need of consolidation. He said he could not offer me any more than that, at this time. I have requested, on several occasions, that Mike propose a merger of Ocata with BioTime.
I would like to ask shareholders to consider such an option and to come up with additional creative suggested alternatives to the current proposed transaction with Astellas. I think they could be vetted and discussed in the blogosphere.
For example, another (non-mutually exclusive) option would be for Ocata to have a Rights Offering for existing shareholders to raise more cash, which it may (or may not) need right now. This would be non-dilutive if all investors participated. If only e.g., 30% participate, it could still raise $30 Million or more, without too great an imposition upon existing shareholders. The Rights Offering could proceed soon. It would give Ocata more time and lessen pressure for it to make any hasty decision.
A third option is to find a billionaire interested in either ophthalmology or the broader potential of cellular therapy. We have already contacted several, as part of our recent efforts. As with many of the companies that we have contacted, many seem to feel that the shortness of time and closed nature of the bidding process would make it a waste of time.
As I understand it, if Ocata gets a majority of shares tendered by 12:00 PM, December 17, 2015, then the deal closes. (EX-99.(a)(1)(C) Ocata 14D-9, p.24, Schedule 14D-9). If not, then Astellas might extend the Offer or even increase its offered price per share, although I would not expect an immediate increase.
If the deal does not close tonight, I respectfully urge Mr. Heffernan and Mr. Wotton to please consider that there has been substantial shareholder objection to the current proposed deal (https://www.bostonglobe.com/business...ROK/story.html) and it would be reasonable and in the interest of shareholders to seriously consider other options. I note that Mr. Wotton expects to receive $3.344 Million as a result of closing the merger with Astellas (Ocata 14D-9, p. 9; Schedule 14D-9), but I hope that he will not let this affect his judgement unduly. If Mr. Heffernan and/or Mr. Wotton feel that they just cannot go on, absent the Astellas merger, I would urge them to consider tendering their resignations sooner, rather than later, so Ocata can begin the search for new leadership.
I think that Drs. Lanza and Langer are key to any new alternatives and I would very much hope that they would stay on. In talking with many industry professionals, Dr. Anglade also seems to be held in very high esteem, not only as a professional, but as a compassionate and sincere person. Great to know!
I think the option of a merger of equals with BioTime makes a lot of sense for several reasons. First, I like Mike West. I think he is very smart and knowledgeable about the field. He is the Father of Stem Cell Therapy.
He “gets it!” He sees the big picture and the potential of the field. Many of Ocata’s patented inventions were invented by him. He understands the technology very well.
Most importantly, Mike is VERY dedicated to these technologies and to bettering humanity through them. I do not think he is very concerned at all with self-enrichment. He is a Man with a Mission: to cure all serious diseases on Earth. I really like that! For investors, money will certainly follow such dedication eventually.
A merger would create an entity with a potential market capitalization of over $700 Million. It would become THE industry powerhouse and the THE place for institutional investors to invest in the sector. It would be close enough to $1 Billion market capitalization, that major institutional investors might invest, where otherwise, they might not.
The structure of BioTime already embraces several semi-independent entities. Ocata could contribute several new such entities to this structure. One or more of them could be headed by Dr. Lanza, if he wishes. He is certainly sufficiently smart and knowledgeable to assume a CEO role. It is HIGH TIME for him to step up to this. Certainly, he could hire top Business Development VP’s to conduct continuous contacts with Big Pharma and interested billionaires, while he focuses on the science and technology.
Eventually, ALL will see the light. Big Pharma is very risk-averse, especially with new, breakthrough technologies. However, they CAN and WILL be convinced by clinical data.
BioTime’s Chairman is Alfred D. Kingsley, LLM, JD. (Alfred D. Kingsley J.D.: Executive Profile & Biography - Businessweek). Mr. Kingsley was right-hand man to the iconic Carl Icahn ($21.7 Billion!;https://en.wikipedia.org/wiki/Carl_Icahn) for over 25 years! (Alfred Kingsley | BioTime , Inc. | ZoomInfo.com). Mr. Kingsley certainly knows his way around both Wall Street and biotech and could be of immeasurable help in fund-raising.
I don’t think there would really be any dilution because the companies are of about equal size. Some economies of scale could be realized. Most importantly, both companies are totally committed to stem cell therapeutics. The show must go on! Investors in the field could continue to benefit from its enormous potential without it being subsumed, diluted and buried inside a Big Pharma.
Ocata could also remain independent. With ~$30 Million in cash, it is not in dire straits. I would ask all interested shareholders to suggest new options and begin a debate on their relative merits. Unless, of course, >50% of shares have already been tendered.
Best wishes,
Gary Aronson
|
|
|
|
Post by JHam on Dec 17, 2015 17:33:33 GMT
Just saw this posted elsewhere: OCATA-Update_from_Gary_Aronson_17-Dec-2015
Gary Aronson asked me to post this for him.
We are continuing to contact potential investors into Ocata. I had one glimmer of hope today, hopefully not too late. I spoke again with my friend, Mike West, PhD, CEO of BioTime (BTX). He said that I could relate that he has already gone on the public record as believing that the stem cell therapeutics industry is in need of consolidation. He said he could not offer me any more than that, at this time. I have requested, on several occasions, that Mike propose a merger of Ocata with BioTime.
I would like to ask shareholders to consider such an option and to come up with additional creative suggested alternatives to the current proposed transaction with Astellas. I think they could be vetted and discussed in the blogosphere.
For example, another (non-mutually exclusive) option would be for Ocata to have a Rights Offering for existing shareholders to raise more cash, which it may (or may not) need right now. This would be non-dilutive if all investors participated. If only e.g., 30% participate, it could still raise $30 Million or more, without too great an imposition upon existing shareholders. The Rights Offering could proceed soon. It would give Ocata more time and lessen pressure for it to make any hasty decision.
A third option is to find a billionaire interested in either ophthalmology or the broader potential of cellular therapy. We have already contacted several, as part of our recent efforts. As with many of the companies that we have contacted, many seem to feel that the shortness of time and closed nature of the bidding process would make it a waste of time.
As I understand it, if Ocata gets a majority of shares tendered by 12:00 PM, December 17, 2015, then the deal closes. (EX-99.(a)(1)(C) Ocata 14D-9, p.24, Schedule 14D-9). If not, then Astellas might extend the Offer or even increase its offered price per share, although I would not expect an immediate increase.
If the deal does not close tonight, I respectfully urge Mr. Heffernan and Mr. Wotton to please consider that there has been substantial shareholder objection to the current proposed deal (https://www.bostonglobe.com/business...ROK/story.html) and it would be reasonable and in the interest of shareholders to seriously consider other options. I note that Mr. Wotton expects to receive $3.344 Million as a result of closing the merger with Astellas (Ocata 14D-9, p. 9; Schedule 14D-9), but I hope that he will not let this affect his judgement unduly. If Mr. Heffernan and/or Mr. Wotton feel that they just cannot go on, absent the Astellas merger, I would urge them to consider tendering their resignations sooner, rather than later, so Ocata can begin the search for new leadership.
I think that Drs. Lanza and Langer are key to any new alternatives and I would very much hope that they would stay on. In talking with many industry professionals, Dr. Anglade also seems to be held in very high esteem, not only as a professional, but as a compassionate and sincere person. Great to know!
I think the option of a merger of equals with BioTime makes a lot of sense for several reasons. First, I like Mike West. I think he is very smart and knowledgeable about the field. He is the Father of Stem Cell Therapy.
He “gets it!” He sees the big picture and the potential of the field. Many of Ocata’s patented inventions were invented by him. He understands the technology very well.
Most importantly, Mike is VERY dedicated to these technologies and to bettering humanity through them. I do not think he is very concerned at all with self-enrichment. He is a Man with a Mission: to cure all serious diseases on Earth. I really like that! For investors, money will certainly follow such dedication eventually.
A merger would create an entity with a potential market capitalization of over $700 Million. It would become THE industry powerhouse and the THE place for institutional investors to invest in the sector. It would be close enough to $1 Billion market capitalization, that major institutional investors might invest, where otherwise, they might not.
The structure of BioTime already embraces several semi-independent entities. Ocata could contribute several new such entities to this structure. One or more of them could be headed by Dr. Lanza, if he wishes. He is certainly sufficiently smart and knowledgeable to assume a CEO role. It is HIGH TIME for him to step up to this. Certainly, he could hire top Business Development VP’s to conduct continuous contacts with Big Pharma and interested billionaires, while he focuses on the science and technology.
Eventually, ALL will see the light. Big Pharma is very risk-averse, especially with new, breakthrough technologies. However, they CAN and WILL be convinced by clinical data.
BioTime’s Chairman is Alfred D. Kingsley, LLM, JD. (Alfred D. Kingsley J.D.: Executive Profile & Biography - Businessweek). Mr. Kingsley was right-hand man to the iconic Carl Icahn ($21.7 Billion!;https://en.wikipedia.org/wiki/Carl_Icahn) for over 25 years! (Alfred Kingsley | BioTime , Inc. | ZoomInfo.com). Mr. Kingsley certainly knows his way around both Wall Street and biotech and could be of immeasurable help in fund-raising.
I don’t think there would really be any dilution because the companies are of about equal size. Some economies of scale could be realized. Most importantly, both companies are totally committed to stem cell therapeutics. The show must go on! Investors in the field could continue to benefit from its enormous potential without it being subsumed, diluted and buried inside a Big Pharma.
Ocata could also remain independent. With ~$30 Million in cash, it is not in dire straits. I would ask all interested shareholders to suggest new options and begin a debate on their relative merits. Unless, of course, >50% of shares have already been tendered.
Best wishes,
Gary AronsonSo it looks like in the eleventh hour Gary's final hope is that West will merge BTX with OCAT. I don't see that happening. Even if it did I'd say the chances that West would offer more than what Astellas is offering is slim to none. At least the technology would stay in the US though... |
|
|
|
Post by tunis on Dec 17, 2015 18:39:50 GMT
Sounds like all the big pharmas said no...lol
There is some interesting buyers of the May 10 Call and May May 7.5 Put so who knows.
|
|
|
|
Post by actcfan on Dec 17, 2015 18:49:07 GMT
Selfishly I am really hoping to see this fall under 50% tender just to see what happens.
|
|
|
|
Post by JHam on Dec 17, 2015 20:23:52 GMT
So should we be expecting a PR AH today?
|
|
|
|
Post by vzveteran on Dec 17, 2015 20:32:03 GMT
Why have this deal run all the way to May, if astellas thinks it's in the bag? If it fails I would like to know by what percentage, as it would affect the pricing of any subsequent offer, should we get one.
If it goes through I'll take my chances with the Chancery Court. That's what GA plans to do...
|
|
|
|
Post by imz72 on Dec 17, 2015 20:41:18 GMT
So should we be expecting a PR AH today? The offer is untill midnight, so I expect a PR only tomorrow. From 8-K: "Unless extended pursuant to and in accordance with the terms of this Agreement , the Offer shall remain open until midnight, New York City time, at the end of the 20th business day" |
|
|
|
Post by JHam on Dec 17, 2015 21:08:33 GMT
So should we be expecting a PR AH today? The offer is untill midnight, so I expect a PR only tomorrow. From 8-K: "Unless extended pursuant to and in accordance with the terms of this Agreement , the Offer shall remain open until midnight, New York City time, at the end of the 20th business day" That's right, thanks! |
|
|
|
Post by phoenix200k on Dec 17, 2015 22:17:37 GMT
First of all Mr west and especially btx don't have a pot to piss in so I don't realistically see how a buyout or merger can even happen even if they wanted to.
It was fun reading on the other MB what read like an 11th hour attempt at a stay of execution Ala "I Want to Live" with what's the red heads name?
Will this be pr'd tonight or tomorrow? Seems like whenever the need a share count for bonuses and more shares the results are tallied quick?
|
|
|
|
Post by vzveteran on Dec 17, 2015 22:58:30 GMT
It wasn't that long ago that we were trading at the offer price.
Date Open High Low Close Volume Adj Close*
Nov 28, 2014 6.29 6.39 6.28 6.33 51,600 6.33
Nov 26, 2014 6.29 6.50 6.20 6.35 80,700 6.35
Nov 25, 2014 6.48 6.48 6.22 6.23 60,200 6.23
Nov 24, 2014 6.26 6.50 6.20 6.32 146,900 6.32
Nov 21, 2014 6.40 6.41 6.20 6.20 93,100 6.20
Nov 20, 2014 6.30 6.49 6.29 6.38 90,400 6.38
Nov 19, 2014 6.54 6.69 6.48 6.50 103,400 6.50
Nov 18, 2014 6.74 6.75 6.49 6.54 94,000 6.54
Nov 17, 2014 7.02 7.02 6.66 6.79 135,200 6.79
Nov 14, 2014 7.03 7.25 6.86 7.02 72,100 7.02
Nov 13, 2014 6.84 7.12 6.68 6.97 133,100 6.97
Nov 12, 2014 7.00 7.01 6.60 6.80 125,400 6.80
Nov 11, 2014 6.62 7.09 6.47 7.00 184,600 7.00
Nov 10, 2014 6.69 7.00 6.69 6.80 160,300 6.80
Nov 7, 2014 6.40 6.90 6.35 6.52 140,100 6.52
Nov 6, 2014 6.49 6.60 6.35 6.40 64,300 6.40
Nov 5, 2014 6.32 6.75 6.28 6.65 78,200 6.65
Nov 4, 2014 6.55 6.55 6.20 6.31 149,200 6.31
Nov 3, 2014 6.93 6.99 6.48 6.54 285,000 6.54
Oct 31, 2014 7.03 7.07 6.92 6.93 63,400 6.93
Oct 30, 2014 7.10 7.10 6.87 7.03 77,600 7.03
Oct 29, 2014 7.25 7.26 7.00 7.02 50,800 7.02
Oct 28, 2014 7.11 7.21 6.93 7.07 55,900 7.07
Oct 27, 2014 6.97 7.48 6.97 7.10 180,800 7.10
Oct 24, 2014 6.99 6.99 6.77 6.91 42,300 6.91
Oct 23, 2014 6.89 7.03 6.76 6.88 101,100 6.88
Oct 22, 2014 7.05 7.05 6.89 6.93 139,700 6.93
Oct 21, 2014 7.21 7.25 7.03 7.05 73,300 7.05
Oct 20, 2014 7.15 7.25 6.91 7.08 83,400 7.08
Oct 17, 2014 7.03 7.32 7.00 7.18 148,800 7.18
Oct 16, 2014 7.27 7.40 6.88 6.95 384,100 6.95
Oct 15, 2014 9.03 9.45 7.31 7.69 870,600 7.69
Oct 14, 2014 6.90 8.65 6.88 7.97 399,500 7.97
Oct 13, 2014 6.95 6.95 6.76 6.83 74,900 6.83
Oct 10, 2014 6.85 7.07 6.85 6.96 50,000 6.96
Oct 9, 2014 7.26 7.26 7.00 7.07 88,900 7.07
Oct 8, 2014 7.46 7.48 7.20 7.25 76,000 7.25
Oct 7, 2014 7.41 7.73 7.30 7.42 80,600 7.42
Oct 6, 2014 6.95 7.50 6.95 7.19 86,900 7.19
Oct 3, 2014 6.84 7.04 6.84 6.94 75,100 6.94
Oct 2, 2014 7.01 7.08 6.76 6.92 136,700 6.92
Oct 1, 2014 7.32 7.34 6.80 7.10 171,300 7.10
Sep 30, 2014 7.95 7.96 6.86 7.41 383,600 7.41
Sep 29, 2014 8.12 8.17 7.90 7.95 125,400 7.95
Sep 26, 2014 7.91 8.25 7.91 8.12 107,700 8.12
Sep 25, 2014 7.72 8.55 7.70 7.94 236,700 7.94
Sep 24, 2014 7.85 7.89 7.67 7.75 147,400 7.75
Sep 23, 2014 8.05 8.25 7.70 7.89 231,200 7.89
Sep 22, 2014 8.51 8.55 8.08 8.08 251,900 8.08
Sep 19, 2014 8.66 8.84 8.58 8.74 90,900 8.74
Sep 18, 2014 9.06 9.06 8.60 8.70 111,700 8.70
Sep 17, 2014 8.75 9.03 8.40 8.78 305,800 8.78
Sep 16, 2014 8.95 9.06 8.61 8.79 201,300 8.79
Sep 15, 2014 8.62 9.25 8.18 8.69 299,100 8.69
Sep 12, 2014 8.93 9.15 8.25 8.49 519,200 8.49
Sep 11, 2014 9.49 10.19 8.21 8.85 1,569,000 8.85
Sep 10, 2014 12.05 12.73 10.17 11.12 1,048,500 11.12
Sep 9, 2014 10.40 12.19 10.39 11.73 816,600 11.73
Sep 8, 2014 9.24 10.15 9.22 10.11 531,000 10.11
Sep 5, 2014 8.94 9.43 8.77 9.20 271,200 9.20
Sep 4, 2014 9.13 9.13 8.80 8.85 237,400 8.85
Sep 3, 2014 8.97 9.17 8.52 9.02 316,800 9.02
Sep 2, 2014 7.97 9.10 7.95 8.78 521,500 8.78
Aug 29, 2014 7.84 8.00 7.31 8.00 211,800 8.00
Aug 28, 2014 9.05 9.05 6.01 7.84 190,500 7.84
Aug 28, 2014 1: 100 Stock Split
Aug 27, 2014 0.08 0.08 0.07 0.08 235,500 8.00
|
|
|
|
Post by JHam on Dec 22, 2015 14:19:05 GMT
|
|
|
|
Post by Whidbeygal CM 20/20 on Dec 22, 2015 17:31:42 GMT
I really enjoyed learning about Dr Lanza's research----but, I am very glad that the company is being sold out of the US regulations (and bias against HESC)
|
|
sunny
Junior Member
Posts: 57 
|
Post by sunny on Dec 23, 2015 16:19:25 GMT
I've messaged Mark Zuckerberg about Ocata since he has started the Chan Zuckerberg Initiative. Maybe a concentrated effort to him from all of us might get his attention. Not tendering my shares.  Good luck to everyone! |
|
|
|
Post by thechurchmaus on Dec 23, 2015 20:46:32 GMT
i would bet they PR lanzas new paper after hours today!the weasels!!
|
|
|
|
Post by harlem on Dec 23, 2015 21:09:36 GMT
MGt only wants to close the deal asap and reap their unjust rewards...I see them only doing what helps ASStelas. imo
|
|
|
|
Post by vzveteran on Dec 23, 2015 21:12:33 GMT
Wotton shut shareholders out Immediately after joining the company. Ted was already 2 months into chats with Astellas.
Jeffries was told by the Company to largely DISREGARD the IP when they considered the Valuation.
Radio silence for a year despite slide deck milestones. Silence on mako to at least try to mitigate the sell off, and the pounding we took that led to this ridiculous offer.
100% over pps my ass!
|
|
|
|
Post by harlem on Dec 24, 2015 15:53:52 GMT
Mgt is grab the cash and go == hoping for a Christmas miracle and some fairness/justice -- and YES, with Gary A. leading the way
|
|
So Astellus viewing insider info and suddenly changing from a small JV to wanting to buy the company, and the share price inexplicably being shorted to half its value all happening at around the same time was just a coincidence was it, you fat self-serving greedy b@stard? 
